Prenetics Global Limited Class A Ordinary Share (PRE)

$PRE they just filed for selling new shares, up to 1 billion USD to buy $BTC https://www.sec.gov/Archives/edgar/data/1876431/000162828025035277/ex9912025egmnoticeandproxy.htm https://www.sec.gov/Archives/edgar/data/1876431/000162828025035132/exhibit991riskfactors.htm Andy Cheung, former COO of OKEx, is in Board of Directors

$PRE good trading pattern 2025 with revenue driven by IM8 It can become a very big deal. I’m in with 5.95 average price, volume is increasing every week, IM8 page is growing… compteitors make hundreds of million worse product and less marketing. they’ll do great

$PRE Too slow on executing the BTC treasury strategy

News World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and Shareholder https://marketwirenews.com/news-releases/world-no-1-tennis-star-aryna-sabalenka-joins-preneti-8630968744208617.html $PRE

$PRE gets v

$PRE Shit company chinese scam die

$PRE $WHLR

$PRE $WHLR this is going to follow

$GURE This and $PRE is todays buys looking extremely good for the coming week

$PRE Strap in and get ready for takeoff! 🚀

$PRE $CERO $SBET $SRE this is the next blow up - early as hell

$PRE this is going parabolic soon

$PRE no position, shouldnt this moon? with the crypto news? like everyone else does?

$PRE Shorts will cover @ $11.50

yuge vol for $PRE

$ACB $RBNE $SRRK $ESEA $PRE Feel free to follow me for pre-market and after-hours movers every day. PRE-MARKET MOVERS: Currently Higher After Earnings: -- Korn Ferry (KFY) up 12.3% -- Euroseas (ESEA) up 8.7% -- GMS Inc. (GMS) up 12.6% Currently Also Higher: -- Circle (CRCL) up 2.9% after Senate passes bill to set up stablecoin framework -- Scholar Rock (SRRK) up 6.3% after announcing results from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss -- Prenetics (PRE) up 5.2% after announcing it will divest ACT Genomics to Delta Electronics in $71.78M transaction as well as raising FY24 revenue view Currently LowerAfter Earnings: -- Aurora Cannabis (ACB) down 11.6% Currently Also Lower: -- Robin Energy (RBNE) down 23.8% after pricing 860,000 shares at $5.25 in registered direct offering

$PRE 1H Levels Price: $8.42 (Broken Support pre-market) Support: $8.48 Resistance: $9.00 Low volume zone — watching for breakout catalyst.

$PRE heating up…🔥🔥🔥

$PRE Prenetics Global (+8.5% in pre-market) is trending on @Stocktwits following news of FDA clearance for its ACTOnco genomic profiling test 🚨 Watch for a breakout from this triangle, as price has neared the apex ↕️

$PRE 🚨 Prenetics to divest ACT Genomics to Delta Electronics in $71.78M transaction

$PRE Prenetics raises FY24 reveue view $80M-$100M from $73M-$85M Management increased full-year 2025 revenue guidance to $80M-100M, excluding ACT Genomics, up from the previous range of $73M-85M, demonstrating confidence in the core business trajectory.

$PRE Prenetics to divest ACT Genomics to Delta Electronics in $71.78M transaction Prenetics Global has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings to Delta Electronics. The transaction regarding Delta's acquisition of up to 100% ACT Genomics' shareholdings is valued at up to $71.78M. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately $46M in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of $44M, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately $86M and with $117M pro-forma short term assets, while maintaining a debt-free balance sheet. ACT Genomics' expertise in clinical diagnostics and next-generation sequencing is expected to complement Delta's existing healthcare solutions portfolio, fostering new synergies and growth opportunities in the precision medicine market. The divestment of ACT Genomics marks the completion of Prenetics' strategic transformation, addressing previous investor feedback regarding business complexity while positioning the company for accelerated growth in the high-margin consumer health market. The transaction enables Prenetics to simplify its investment thesis, enhance financial flexibility, accelerate growth focus, and optimize resource allocation.